Jersey Mike's Subs prepares for an IPO amid an active primary-offerings market — Freedom

U.S. fast-food restaurant chain Jersey Mike's Subs has announced the terms of its initial public offering (IPO). The company plans to offer about 43.48 million shares, some of which will be sold by the company and some by existing shareholders. The shares are expected to list on the New York Stock Exchange under the ticker JMKE.

About Jersey Mike's Subs

Jersey Mike's Subs is an American restaurant chain specializing in sandwiches. The company was founded in 1956 and today is among the largest players in the fast-casual segment in the U.S. The chain has more than 3,300 restaurants, predominantly operating under a franchise model, and its main shareholder is investment firm Blackstone.

According to the published offering terms, Jersey Mike's intends to offer investors about 13.8 million new shares, while existing shareholders will sell another roughly 29.7 million shares. The IPO price range is set at $21–25 per share. If priced at the top of the range, the company’s market capitalization could be about $7.94 billion, or nearly $8 billion. Investment firm Blackstone will retain control of the company after the listing. 

Why Jersey Mike's IPO may interest investors 

Freedom Broker analyst Natalia Milchakova believes Jersey Mike's Subs’ move to go public is driven by the need to raise capital for further business scaling and expansion of its restaurant network in the U.S. and Canada.

In the expert’s view, current conditions in the U.S. market are favorable for conducting IPOs. In 2026, activity in the primary market reached one of its highest levels in recent years, creating supportive conditions for companies demonstrating steady growth.

Natalia Milchakova notes that Jersey Mike's shares may attract investors thanks to strong operating performance, rapid network expansion, and high customer loyalty.

Which IPOs Freedom Broker is watching

Earlier, we wrote that biotechnology company Scribe Therapeutics filed for an IPO, aiming to raise up to $107.2 million. The company develops genome-editing technologies and is working on new approaches to treating severe diseases. Going public will allow Scribe Therapeutics to secure additional funding to continue research and develop its own platform.

Another notable offering was the IPO of Latigo Biotherapeutics, which also filed to go public to raise capital for the development of innovative drugs. The company specializes in developing therapeutic solutions in medicine and expects to use the proceeds to advance its research programs.

In addition, the U.S. market saw the completion of the IPO of SPAC company AMR Resources Acquisition. The offering was priced at $10 per share. The SPAC model remains one of the tools companies use to enter the public market, helping accelerate the process of raising investment and finding promising assets to combine with.

Investors also took notice of the IPO of technology company CSquare. In the offering, shares were sold to the market at $21 per share. The company’s listing reflects sustained investor interest in the technology sector and in companies focused on developing digital solutions and innovative products.

Freedom Broker continues to monitor new U.S.-market offerings, providing investors with information on key events in the IPO segment and the opportunities opening up for stock-market participants.

This is not an individual investment recommendation.